Leonard Schleifer (AP Images)

Re­gen­eron adds more pos­i­tive PhI­II da­ta for its NGF pro­gram — but safe­ty is still a big con­cern

Two years af­ter fas­inum­ab hit its first late-stage bar, Re­gen­eron is stand­ing by its “high-risk, high re­ward” bet on the NGF an­ti­body. But while new Phase III da­ta so­lid­i­fied the po­ten­tial re­ward, the risk is still threat­en­ing to blow it all up.

Re­gen­eron ex­ecs and an­a­lysts alike now have their eyes set on a ri­val drug from Pfiz­er and Eli Lil­ly, whose fate at the FDA will like­ly set the scene for the class.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.